by David Twigg (freelance writer, Sheffield, England) (Reprinted here with permission from https://www.edel-optics.co.uk/Retinitis-Pigmentosa.html) Retinitis Pigmentosa covers a group of eye conditions affecting the retina, leading to sight problems and loss of vision. It is one of the conditions falling under the heading of Rod-Cone Dystrophy, genetic conditions in which the rod and cone cells in the eye deteriorate […]
NIH-funded study points to converging factors that drive disease-related inflammation People with a genetic predisposition for age-related macular degeneration (AMD) significantly increased their odds of developing the blinding eye disorder if they had a history of heavy smoking and consistently did not exercise or eat enough fruits and vegetables, according to an observational study of […]
Prevent Blindness, the nation’s oldest volunteer eye health and safety organization, has launched a unique new resource, “GuideMe”, designed for those who have been diagnosed with Age-related Macular Degeneration (AMD) or Diabetic Macular Edema (DME). The intent of the GuideMe books is to simulate as accurately as possible a post-diagnosis consultation with a doctor or therapist. They […]
Results from First Cohort Expected in the Second Quarter of 2016 Acucela (formerly Ocata) has announced that the first patient has been enrolled in the company’s Phase 2 clinical trial using Ocata’s proprietary RPE cells in patients with atrophic (dry) age-related macular degeneration (AMD). The purpose of the trial is to evaluate safety and explore efficacy as compared […]
Neurotech Pharmaceuticals, Inc. has announced that they have enrolled the first patient in their multicenter Phase 2 clinical trial of NT-503 Encapsulated Cell Therapy (ECT) for the long-term treatment of wet macular degeneration (AMD). NT-503 is a unique vascular endothelial growth factor (VEGF) receptor protein continuously produced by Neurotech’s versatile ECT implant. “This landmark proof-of-concept […]